# Aliskiren/Amlodipine/Hydrochlorothiazide (HCTZ) Versus Aliskiren/Amlodipine in US Minority Patients With Stage II Systolic Hypertension

> **NCT00942994** · PHASE4 · COMPLETED · sponsor: **Novartis** · enrollment: 412 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Aliskiren/Amlodipine
- **DRUG:** Aliskiren/Amlodipine and Hydrochlorothiazide (HCTZ)

## Key facts

- **NCT ID:** NCT00942994
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2010-03
- **Final completion:** —
- **Target enrollment:** 412 (ACTUAL)
- **Last updated:** 2011-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00942994

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00942994, "Aliskiren/Amlodipine/Hydrochlorothiazide (HCTZ) Versus Aliskiren/Amlodipine in US Minority Patients With Stage II Systolic Hypertension". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00942994. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*